A Phase 1 study of KRN23

A Phase 1 study of KRN23 in Subjects with X-linked Hypophosphatemic Rickets/Osteomalacia

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222550

Enrollment

Registered

2014-07-02

Start date

2014-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-linked Hypophosphatemic Rickets/Osteomalacia

Interventions

investigational material(s) Generic name etc : KRN23 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with XLH

Exclusion criteria

Exclusion criteria: 1. Have an active infection or chronic inflammatory disease 2. Have uncontrolled hypertension 3. Have uncontrolled diabetes mellitus 4. History of known immunodeficiency 5. Use of a pharmacologic vitamin D, or its metabolite or its analogs within 21 days prior to screening and after screening 6. Use of phosphate, calcium preparation, calcimimetics, aluminum hydroxide antacids, thiazide diuretic, acetazolamide, or phosphate, calcium, and/or vitamin D-containing supplements within 10 days prior to screening and after screening 7. Pregnant or lactating females, women who are possibly pregnant or patients who have no intention of utilizing adequate contraception

Design outcomes

Primary

Measure	Time frame
Safety Adverse events, laboratory tests	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026